Quantinno Capital Management LP Sells 168,471 Shares of Perrigo Company plc $PRGO

Quantinno Capital Management LP cut its holdings in Perrigo Company plc (NYSE:PRGO) by 25.4% in the first quarter, Holdings Channel reports. The fund owned 493,866 shares of the company’s stock after selling 168,471 shares during the quarter. Quantinno Capital Management LP’s holdings in Perrigo were worth $5,304,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Perrigo by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after purchasing an additional 653,925 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Perrigo by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Perrigo by 291.9% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after buying an additional 5,828,076 shares during the period. State Street Corp raised its stake in Perrigo by 9.5% in the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after buying an additional 637,678 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC lifted its holdings in Perrigo by 28.4% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after buying an additional 1,029,770 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Price Performance

Shares of PRGO opened at $12.53 on Friday. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -1.00, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. Perrigo Company plc has a twelve month low of $9.23 and a twelve month high of $24.60. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average of $10.58 and a two-hundred day moving average of $11.53.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the firm posted ($0.06) earnings per share. The business’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts predict that Perrigo Company plc will post 2.4 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 9.3%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s dividend payout ratio is currently -8.85%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.33.

Trending Headlines about Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.50, well above the $0.31 analyst consensus, while revenue of approximately $1.02 billion was in line with estimates. The company also returned to profitability compared with a loss in the prior-year quarter. Perrigo Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Infant Formula sales increased 23.1%, supported by contract-shipment timing and stronger store-brand formula demand, helping offset weaker performance in other categories. Perrigo Stock Rises as Q2 Earnings and Sales Beat Estimates
• Positive Sentiment: Perrigo reaffirmed its full-year 2026 outlook and provided EPS guidance of $2.25-$2.55, above the $2.11 consensus estimate. Management expects a stronger second half and cited market-share gains in U.S. store-brand over-the-counter products and key European brands. Perrigo Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: The company completed its Dermacosmetics divestiture and continues strategic reviews of its Infant Formula and Oral Care businesses, signaling portfolio streamlining but also uncertainty around future growth drivers.
• Negative Sentiment: Second-quarter net sales fell roughly 3.1%-3.2% year over year, core organic sales declined 3.5%, and management acknowledged softer category demand and macroeconomic headwinds. Total debt stood at approximately $3.3 billion versus $400 million of cash, which may keep investors cautious despite the earnings beat. Perrigo Q2 Net Sales Fall

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.